ABSTRACT
GT-1a or 18) . 85 The pharmacokinetic profile of faldaprevir supports QD administration (19) . 
RESULTS

243
Demographics
244
Demographic data are summarized in (Figure 2 and Table 2 ). After reaching the maximum, faldaprevir concentrations declined, first in a rapid biphasic manner, 257 followed by a slower terminal elimination phase (Figure 2) moderate, and severe renal impairment, respectively; Table 2 ).
261
The highest gMean faldaprevir exposures were in subjects with moderate renal 262 impairment ( Table 2) . gMean values of C max were 3,810 ng/mL in subjects with 263 normal renal function, and 4,080 ng/mL, 6,680 ng/mL, and 4,600 ng/mL in 264 subjects with mild, moderate, and severe renal impairment, respectively.
265
Similarly, gMean values of AUC 0-∞ were 76,500 ng·h/mL in subjects with normal 266 renal function, and 86,900 ng·h/mL, 136,000 ng·h/mL, and 129,000 ng·h/mL in 267 subjects with mild, moderate, and severe renal impairment, respectively.
268
However, the inter-subject variability was high for both C max and AUC (Supplementary Figure 1) . 
